John Hood, Endeavor BioMedicines CEO
April 24, 2024 07:30 AM EDTUpdated 08:41 AM
Financing
Startups

En­deav­or Bio­Med­i­cines snags $132M for Phase 2 fi­bro­sis drug, ADC can­di­date

Kyle LaHucik

Senior Reporter

San Diego biotech En­deav­or Bio­Med­i­cines is on a tear.

The start­up has se­cured a $132.5 mil­lion Se­ries C af­ter hir­ing four C-suite lead­ers,

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

The End­points 2024 win­ners and losers list: Who was up and who was down in bio­phar­ma

Up­dat­ed: No­vo’s 23% weight loss with Ca­griSe­ma falls short of high ex­pec­ta­tions, new tri­al planned

Mer­ck’s long-await­ed obe­si­ty move is an oral GLP-1 from Chi­na

Ma­jor PBM re­forms fea­ture in Con­gress' year-end spend­ing bill

What Trump’s FTC picks mean for bio­phar­ma deal­mak­ing and PBMs

Up­dat­ed: Ver­tex’s non-opi­oid pill dis­ap­points in mid-stage chron­ic pain study

A service from the Financial Times